Griffo Botanicals – FDA Warning Letter, Oct 1, 2020
On October 7, 2020, the FDA and FTC issued a Warning Letter to Griffo Botanicals regarding unapproved and misbranded herbal tincture products marketed for COVID-19. The agencies reviewed the company's websites (griffobotanicals.com, facebook.com/griffobotanicals, instagram.com/griffobotanicals) on September 15 and October 1, 2020.
The FDA determined that the products are unapproved new drugs under Section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) because they are intended to mitigate, prevent, treat, diagnose, or cure COVID-19. They are also misbranded drugs under Section 502 (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited by Sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)). The FTC found that claims of preventing, treating, or curing COVID-19 lack competent and reliable scientific evidence, violating the FTC Act (15 U.S.C. 41 et seq.).
Griffo Botanicals must immediately cease selling these unapproved products and remove all COVID-19-related claims. Within 48 hours,
ID · eae10c6e-11f0-415f-948b-23f1b58845b3
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.